-
Mashup Score: 0Gemtuzumab Ozogamicin Plus Intensive Chemotherapy Reduces Cumulative Incidence of Relapse Among Patients With NPM1-Mutated AML - 7 month(s) ago
The addition of gemtuzumab ozogamicin to intensive chemotherapy reduced the cumulative incidence of relapse among patients with newly diagnosed NPM1-mutated acute myeloid leukemia, according to findings from a phase 3 trial.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Triplet vs Quadruplet Regimen for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma - 7 month(s) ago
Stefan Knop, MD, presents initial results from a randomized phase 3 study of triplet vs quadruplet therapeutic regimen for patients with newly diagnosed transplant-eligible multiple myeloma.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Stefan Knop, MD, presents initial results from a randomized phase 3 study of triplet vs quadruplet therapeutic regimen for patients with newly diagnosed transplant-eligible #MultipleMyeloma, which he presented at #ASCO2023. Learn more: https://t.co/EHhy2LNZbC @ASCO #OncologyNews https://t.co/Yz6T8kdxfN
-
-
Mashup Score: 0
Benjamin Watkins, MD, discusses optimal options and strategies to employ for the prevention of the development of graft-versus-host disease following allogeneic stem cell transplant.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Here, Benjamin Watkins, MD, discusses optimal options and strategies to employ for the prevention of the development of graft-versus-host disease following allogeneic stem cell transplant. Learn more: https://t.co/t6RvnfFhhK @TulaneMedicine #GVHD #OncologyNews https://t.co/VQi7OyRywf
-
-
Mashup Score: 1Oral Azacitidine Plus CHOP Demonstrates Safety, Efficacy for Patients With Peripheral T-Cell Lymphomas With T-Follicular Helper Phenotype - 7 month(s) ago
A phase 2 trial indicated that the combination of oral azacitidine plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) as initial treatment for patients with peripheral T-cell lymphomas with T-follicular helper phenotype demonstrated safety and high rates of complete response.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
According to Jia Ruan, MD, and coauthors, "Addition of oral #azacitidine to CHOP as initial therapy is safe, and induces high rates of [complete response] in patients with PTCL-TFH." Read more: https://t.co/zqkCdizDmu @WeillCornell #Oncology #OncologyNews #CancerNews https://t.co/Fe2TnQkKIx
-
-
Mashup Score: 0R-CHOP Plus R-BAC Shows Potential as Induction Therapy for Transplant-Eligible Patients With MCL - 7 month(s) ago
The combination of R-CHOP and R-BAC demonstrated efficacy as a potential induction therapy option for transplant-eligible patients with mantle cell lymphoma, according to a retrospective analysis.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Yuki Shimizu, MD, and coauthors concluded, "To the best of our knowledge, this is the first report that demonstrates the use of R-CHOP/R-BAC therapy as induction therapy prior to HDC/ASCT." Learn more: https://t.co/SgEZje1Vvj #Oncology #OncologyNews #CancerNews #MCL https://t.co/TYQAThVQMG
-
-
Mashup Score: 0
Benjamin Watkins, MD, provides insights into the latest research regarding patients treated with immunomodulator abatacept for the prevention of graft-versus-host disease.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In this video, Benjamin Watkins, MD, provides the latest research and data including real-world analyses of patients treated with immunomodulator abatacept for the prevention of graft-versus-host-disease #GVHD. Learn more: https://t.co/MESjocZDws @TulaneMedicine #OncologyNews https://t.co/kCkKN4usGE
-
-
Mashup Score: 0Predictive Value of CIRS-Derived Comorbidity Index for Patients With R/R DLBCL Indicated for CAR T-Cell Therapy - 7 month(s) ago
A simplified CIRS-derived comorbidity index predicted outcomes among patients with R/R diffuse large B-cell lymphoma indicated for CAR T-cell therapy, according to a retrospective analysis.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
According to Geoffrey Shouse, DO, MPH, “Adverse outcomes for patients with #DLBCL meant to receive CAR T can be predicted using a simplified CIRS-derived comorbidity index.” Learn more: https://t.co/cv4TErotmy @cityofhope #OncologyNews #Oncology https://t.co/lIGXlBY2Sq
-
-
Mashup Score: 1FDA Grants Accelerated Approval to Talquetamab for Patients With R/R Multiple Myeloma - 8 month(s) ago
On August 9, 2023, the FDA granted accelerated approval to talquetamab for adult patients with relapsed/refractory MM who received 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Exciting news! On August 9, 2023, the #FDA granted accelerated approval to #talquetamab for the treatment of adult patients with R/R #MultipleMyeloma. Learn more: https://t.co/4SHUwEmXgs #MM #FDAApproval #OncologyNews @FDAOncology https://t.co/AVtUbiQm4y
-
-
Mashup Score: 0Wolters Kluwer Subscription Pages - 12 month(s) ago
Sign up for our free e-newsletter and receive email notification when each issue becomes available and when other new content is posted online. New to Oncology Times? Visit the publication’s website at www.oncology-times.com where you can get free access to archived issues, subscribe to the print newspaper, download the OT app, and create your own personal online article…
Source: wolterskluwer.omeda.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Sign up for the Oncology Times eNewsletter to get top stories delivered to your inbox every week! Sign up here: https://t.co/6316dz5fdA #OncologyNews #MedTwitter #OncologySM #OncologyResearch https://t.co/BA6wjMXkmw
-
-
Mashup Score: 0Wolters Kluwer Health - 12 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Interested in seeing your name in print? Oncology Times is seeking new #clinician writers to contribute! Learn more: https://t.co/jJHjxakUBl #OncologyNews #MedTwitter https://t.co/I6gWtwqM7x
-
Hartmut Döhner, MD, and coauthors stated, "the addition of #gemtuzumab #ozogamicin might reduce the need for salvage therapy in these participants." Learn more: https://t.co/wzvUXUjuvE #AML #AcuteMyeloidLeukemia #Leukemia #Oncology #OncologyNews https://t.co/Mj3WNdbOA8